72 related articles for article (PubMed ID: 29359606)
1. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
Lee S; Xie L; Wang Y; Vaidya N; Baser O
J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
[TBL] [Abstract][Full Text] [Related]
4. Clinical Burden of Concomitant Joint Disease in Psoriasis: A US-Linked Claims and Electronic Health Records Database Analysis.
Skornicki M; Prince P; Suruki R; Lee E; Louder A
Adv Ther; 2021 May; 38(5):2458-2471. PubMed ID: 33818686
[TBL] [Abstract][Full Text] [Related]
5. Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.
Kaine J; Song X; Kim G; Hur P; Palmer JB
J Manag Care Spec Pharm; 2019 Jan; 25(1):122-132. PubMed ID: 29694270
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
[TBL] [Abstract][Full Text] [Related]
7. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
[TBL] [Abstract][Full Text] [Related]
9. Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis.
Truong B; Rich-Garg N; Ehst BD; Deodhar AA; Ku JH; Vakil-Gilani K; Danve A; Blauvelt A
Clin Cosmet Investig Dermatol; 2015; 8():563-9. PubMed ID: 26622188
[TBL] [Abstract][Full Text] [Related]
10. The clinical and economic burden of newly diagnosed Alzheimer's disease in a medicare advantage population.
Suehs BT; Davis CD; Alvir J; van Amerongen D; Pharmd NC; Joshi AV; Faison WE; Shah SN
Am J Alzheimers Dis Other Demen; 2013 Jun; 28(4):384-92. PubMed ID: 23687180
[TBL] [Abstract][Full Text] [Related]
11. Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study.
Eder L; Harvey P; Chandran V; Rosen CF; Dutz J; Elder JT; Rahman P; Ritchlin CT; Rohekar S; Hayday R; Barac S; Feld J; Zisman D; Gladman DD
J Rheumatol; 2018 Mar; 45(3):378-384. PubMed ID: 29419462
[TBL] [Abstract][Full Text] [Related]
12. The impact of psoriasis on professional life: PsoPRO, a French national survey.
Claudepierre P; Lahfa M; Levy P; Barnetche T; Bonnet I; Aubert R; Roquelaure Y
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1702-1709. PubMed ID: 29633363
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of pediatric psoriasis: A nationwide cohort study in Taiwan.
Lin TL; Fan YH; Chang YL; Ho HJ; Wu CY; Chen YJ
J Dermatol; 2024 Jan; 51(1):48-55. PubMed ID: 37870277
[TBL] [Abstract][Full Text] [Related]
14. Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study.
Nguyen HT; Vu AT; Pham NTU; Tran TNA; Pham NN; Bui HTT; Pham TT; Dinh VTT; Bui YT; Vu TTP
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3193-3208. PubMed ID: 37978119
[TBL] [Abstract][Full Text] [Related]
15. Comorbidities among adult patients with psoriasis in Tianjin: a cross-sectional analysis of the Health Database study.
Zhang Y; Guo Y; Zhang K; Fan L; Ma J; Li Y; Zhou Q; Zhao Q; Hou S; Wang H
BMJ Open; 2024 May; 14(5):e083683. PubMed ID: 38772892
[TBL] [Abstract][Full Text] [Related]
16. Changes in Healthcare Spending After Diagnosis of Comorbidities Among Endometriosis Patients: A Difference-in-Differences Analysis.
Epstein AJ; Soliman AM; Davis M; Johnson SJ; Snabes MC; Surrey ES
Adv Ther; 2017 Nov; 34(11):2491-2502. PubMed ID: 29101714
[TBL] [Abstract][Full Text] [Related]
17. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities.
Brandon TG; Manos CK; Xiao R; Ogdie A; Weiss PF
J Psoriasis Psoriatic Arthritis; 2018 Oct; 3(4):131-136. PubMed ID: 31355354
[TBL] [Abstract][Full Text] [Related]
18. Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.
Puig L; Fernández-Freire LR; Burgos-Pol R; Gomez I; Peral C; Gomez S; Rebollo Laserna FJ
Dermatol Ther (Heidelb); 2019 Sep; 9(3):479-496. PubMed ID: 31062222
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set.
Walsh JA; Song X; Kim G; Park Y
Clin Rheumatol; 2018 Jul; 37(7):1869-1878. PubMed ID: 29637483
[TBL] [Abstract][Full Text] [Related]
20. Real-world burden of comorbidities in US patients with psoriatic arthritis.
Shah K; Paris M; Mellars L; Changolkar A; Mease PJ
RMD Open; 2017; 3(2):e000588. PubMed ID: 29435363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
